Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine

Influenza is an important cause of serious illness in very young children with cardiopulmonary disease. A 4-year study was conducted at two centers to assess immunogenicity and safety of influenza split-product vaccine in children aged 3 to 18 months with bronchopulmonary dysplasia and congenital he...

Ausführliche Beschreibung